Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eliquis

Bristol Myers Squibb logo

BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study

Breyanzi demonstrated a statistically significant improvement in event-free survival compared to standard of care

- PMLiVE

BMS’ Zeposia gains FDA approval in ulcerative colitis

Treatment was initially approved in 2020 for multiple sclerosis

- PMLiVE

BMS links up with Exscientia for $1.2bn AI drug discovery deal

Deal focuses on the use of AI to discover drug candidates across a number of therapeutic areas

- PMLiVE

BMS builds case for cardiovascular drug mavacamten with new analysis

BMS initially picked up mavacamten as part of its $13.1bn acquisition of MyoKardia last year

- PMLiVE

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

Checkpoint inhibitor plus tyrosine kinase inhibitor approved for the first-line treatment of advanced renal cell carcinoma

- PMLiVE

Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients

Combination increases complete response rate to 24% compared to chemotherapy alone

- PMLiVE

BMS and bluebird bio gain FDA approval for multiple myeloma therapy

Abecma is a CAR T cell therapy approved for pre-treated myeloma patients

- PMLiVE

FDA accepts BMS’ investigational cardiovascular drug mavacamten for review

BMS gained the rights to mavacamten as part of its acquisition of MyoKardia

- PMLiVE

FDA advisory committee to review oncology accelerated approvals

Review comes after voluntary indication withdrawals for a number of cancer therapies

- PMLiVE

BMS links up with Molecular Templates for oncology research collaboration

Deal could be worth up to $1.3bn in milestone payments

- PMLiVE

BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

Combination also demonstrated benefit in sarcomatoid subgroup with poor prognoses

- PMLiVE

FDA approves BMS’ blood cancer CAR T therapy after delay

The FDA's approval of Breyanzi came a year after the start of the review

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links